Clinical Trial Update: An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

View source ↗

Summary

A report on an early access program for ustekinumab in participants with moderately to severely active Crohn's disease, noting that the program is no longer ava…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Status: NO_LONGER_AVAILABLE